Ozempic (semaglutide) Letter of Medical Necessity
Ozempic (semaglutide) denials almost always cite A1c thresholds, metformin trial documentation, or off-label weight-loss use. A precise LMN that addresses the on-label T2DM indication with supporting labs is essential. For payer-by-payer criteria across all GLP-1 agents, see our GLP-1 Prior Authorization Guide.
FDA-Approved Indications
- ● type 2 diabetes mellitus
- ● cardiovascular risk reduction in T2DM with established CVD
Why Ozempic Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. A1c criterion not met (typically requires >7%)
- 2. Metformin trial not documented
- 3. Off-label use for weight loss (Wegovy is the approved weight-loss formulation)
- 4. Quantity limit exceeded
- 5. Tier exception requested without justification
What to Include in a Ozempic Letter of Medical Necessity
Document T2DM diagnosis with recent A1c, BMI, prior antihyperglycemic agents tried with response/intolerance, and cardiovascular risk factors. For patients with established ASCVD, cite SUSTAIN-6 outcomes data supporting semaglutide for CV risk reduction.
Key clinical evidence to cite:
- ✓ SUSTAIN-1 through SUSTAIN-10 trials
- ✓ SUSTAIN-6 cardiovascular outcomes trial
- ✓ PIONEER program for oral semaglutide comparison
Relevant guidelines:
- 📖 ADA 2024 Standards of Care
- 📖 AACE 2022 T2DM Algorithm
- 📖 ESC 2023 CV Risk Guidelines
Ozempic Prior Authorization Criteria
Standard criteria across major US payers for Ozempic. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Metformin trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Ozempic
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Ozempic Prior Authorization FAQ
Why was my Ozempic prior authorization denied?
The most common denial reasons for Ozempic are: A1c criterion not met (typically requires >7%); Metformin trial not documented; Off-label use for weight loss (Wegovy is the approved weight-loss formulation); Quantity limit exceeded; Tier exception requested without justification.
What should a Ozempic Letter of Medical Necessity include?
Document T2DM diagnosis with recent A1c, BMI, prior antihyperglycemic agents tried with response/intolerance, and cardiovascular risk factors. For patients with established ASCVD, cite SUSTAIN-6 outcomes data supporting semaglutide for CV risk reduction.
Which payers cover Ozempic?
Ozempic is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Express Scripts, CVS Caremark, though formulary tier and prior authorization criteria vary.